0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FGF R2 (IIIc)

FGF R2 (IIIc)

Brief Information

Name:Fibroblast growth factor receptor 2
Target Synonym:EC:2.7.10.1,BEK,K-sam,KGFR,FGFR2,Fibroblast Growth Factor Receptor 2,Keratinocyte Growth Factor Receptor,Bacteria-Expressed Kinase,Protein Tyrosine Kinase, Receptor Like 14,BEK Fibroblast Growth Factor Receptor,Craniofacial Dysostosis 1,Jackson-Weiss Synd
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:18
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
FGC-H5225 Human Human FGF R2 (IIIc) protein, His Tag (MALS verified)
FGC-H5225-structure
FGC-H5225-sds
FGC-H5225-elisa_1

Part of Bioactivity data

FGC-H5225-MALS-HPLC
Human FGFR2 (IIIc), His Tag (Cat. No. ) MALS images

The purity of Human FGFR2 (IIIc), His Tag(Cat. No. FGC-H5225) was more than 90% and the molecular weight of this protein is around 45-55 kDa verified by SEC-MALS.

Bioactivity-ELISA
Human FGFR2 (IIIc), His TagHuman FGFR2 (IIIc), His Tag (Cat. No. FGC-H5225) ELISA bioactivity

Immobilized Human FGFR2 (IIIc), His Tag (Cat. No. FGC-H5225) at 5 μg/mL (100 μL/well) can bind Biotinylated Human FGF basic, Tag Free with a linear range of 0.04-1.25 μg/mL (Routinely tested).

FGC-H5225-ELISA
Human FGFR2 (IIIc), His TagHuman FGFR2 (IIIc), His Tag (Cat. No. FGC-H5225) ELISA bioactivity

Immobilized Human FGFR2 (IIIc), His Tag (Cat. No. FGC-H5225) at 5 μg/mL (100 μL/well) can bind Biotinylated Human FGF basic, Tag Free with a linear range of 0.04-1.25 μg/mL (Routinely tested).

Synonym Name

FGF R2 (IIIc),FGFR2B,FGFR2

Background

Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Erdafitinib G-024; JNJ-493; 890E37NHMV; JNJ-42756493 Approved Astex Pharmaceuticals Inc Balversa United States Carcinoma, Transitional Cell Janssen Biotech Inc 2019-04-12 Solid tumours; Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Hepatic Insufficiency; Lymphoma; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
Regorafenib Monohydrate BAY-73-4506; DAST Approved Bayer Ag Stivarga, Resihance Mainland China Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Solid tumours; Rectal Neoplasms; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details
Pemigatinib IBI-375; INCB-054828; INCB-54828; BH-009 Approved Incyte Corp Pemazyre, 达伯坦, 伯坦 Taiwan Cholangiocarcinoma Incyte Corp 2020-04-17 Biliary Tract Neoplasms; Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Translocation, Genetic; Bile Duct Neoplasms; Endometrial Neoplasms Details
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Small Cell Lung Carcinoma Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Esophageal Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Gastrointestinal Stromal Tumors; Bone Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Thyroid Neoplasms; Sarcoma, Alveolar Soft Part; Cholangiocarcinoma; Lung Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Adenocarcinoma; Osteoma; Triple Negative Breast Neoplasms; Solid tumours; Ovarian Neoplasms; Leiomyosarcoma; Liver Neoplasms; Genital Diseases, Female; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Biliary Tract Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Sarcoma, Synovial; Neuroendocrine Tumors; Medullary thyroid cancer (MTC); Sarcoma Details
Infigratinib BGJ-398; NVP-BGJ398 Approved Novartis Pharma Ag TRUSELTIQ United States Cholangiocarcinoma Qed Therapeutics Inc 2021-05-28 Solid tumours; Biliary Tract Neoplasms; Hematologic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Achondroplasia; Urinary Bladder Neoplasms; Cholangiocarcinoma; Carcinoma, Squamous Cell; Melanoma Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef Mainland China Idiopathic Pulmonary Fibrosis Boehringer Ingelheim International Gmbh 2014-10-15 Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Scleroderma, Systemic; Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Lung Diseases, Interstitial; Multiple Myeloma; Prostatic Neoplasms; Peritoneal Neoplasms; Hepatic Insufficiency; Genital Neoplasms, Female; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Lenvatinib Mesylate ER-203492-00; E-7080 Approved Eisai Co Ltd Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 United States Endometrial Neoplasms Eisai Inc 2015-02-13 Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gallbladder Neoplasms; Lymphoma; Endometrial Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Cholangiocarcinoma; Sarcoma; Liver Diseases; Liver Neoplasms; Triple Negative Breast Neoplasms; Kidney Diseases; Small Cell Lung Carcinoma; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Esophageal Neoplasms; Renal Insufficiency; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Biliary Tract Neoplasms; Solid tumours Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
S-49076 S-49076 Phase 2 Clinical Servier Glioblastoma; Carcinoma, Non-Small-Cell Lung Details
LY-2874455 LY-2874455 Phase 2 Clinical Eli Lilly And Company Neoplasms Details
E-7090 E-7090 Phase 2 Clinical Eisai Co Ltd Biliary Tract Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Hepatic Insufficiency Details
HMPL-453 tartrate Phase 2 Clinical Hutchison Huangpu Medicine (Shanghai) Co Ltd Biliary Tract Neoplasms; Solid tumours; Head and Neck Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid; Neoplasms, Mesothelial; Stomach Neoplasms; Esophageal Neoplasms; Mesothelioma; Multiple Myeloma; Urinary Bladder Neoplasms; Breast Neoplasms; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Aprutumab ixadotin BAY-1187982 Phase 1 Clinical Bayer Ag Neoplasms Details
Alofanib RPT-835 Phase 1 Clinical Russian Pharmaceutical Technologies Llc Stomach Neoplasms Details
PRN-1371 PRN-1371 Phase 1 Clinical Principia Biopharma Inc Solid tumours; Urinary Bladder Neoplasms Details
RLY-4008 RLY-4008 Phase 1 Clinical Relay Therapeutics Inc Solid tumours; Stomach Neoplasms; Translocation, Genetic; Breast Neoplasms; Cholangiocarcinoma; Endometrial Neoplasms Details
CH-5183284 FF-284; CH-5183284; Debio-1347 Phase 2 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Breast Neoplasms Details
Recombinant human keratinocyte growth factor-2 (Newsummit biopharma) Phase 3 Clinical Wuhan Optics Valley New Medicine Incubation Public Service Platform Co Ltd Burns Details
Aprutumab FGFR-moAb; FGFR2-TTC; BAY-1179470 Phase 1 Clinical Bayer Ag Neoplasms Details
Lucitanib AL-3810; CO-3810; S-80881 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Thymus Neoplasms; Genital Neoplasms, Female; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Recombinant human keratinocyte growth factor-2 (Guangdong Jida Gene Research Center) Phase 1 Clinical Guangzhou Jida Gene Pharmacy Engineering Research Center Co Ltd Keratitis; Corneal Injuries; Corneal Diseases Details
BPI-17509 BPI-17509 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours Details
TT-00434 TT-00434 Phase 1 Clinical Yaojie Ankang (Nanjing) Technology Co Ltd Solid tumours; Urinary Bladder Neoplasms Details
HH185 3-D185; HH-185; 3D185; 3D-185 Phase 1 Clinical Shanghai Medicilon Inc, ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Solid tumours Details
Futibatinib TAS-120 Phase 3 Clinical Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd Bone Marrow Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma; Carcinoma, Transitional Cell; Brain Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung Details
Bemarituzumab FPA-144 Phase 2 Clinical Five Prime Therapeutics Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Gastrointestinal Neoplasms Details

This web search service is supported by Google Inc.

totop